All In Biotech

Drug Trial Radar · NCT06264414

Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Phase III, Multicenter, Randomized, Double-blind Clinical Trial to Assess the Efficacy and Safety of the DTT106 in the Treatment of Erectile Dysfunction Associated With Benign Prostatic Hyperplasia

Last checked: Nov 19, 2026Latest source record: Feb 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 262 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

262

Planned (sponsor's estimate)

Start

Feb 2025

Primary completion

Jun 2026

Study completion Jul 2027

Sponsor

Lead sponsor
EMSIndustry
Sponsor type
Industry
First posted
Feb 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety and efficacy of the DTT106 in the treatment of erectile dysfunction associated with benign prostatic hyperplasia

Conditions

  • Prostatic Hyperplasia, Benign
  • Erectile Dysfunction

Interventions

  • DTT106Drug

    oral route

  • Dutasteride-TamsulosinDrug

    oral route

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in the Erectile Function domain score of the International Index of Erectile Function (IIEF-EF) at the end of treatment, from baseline.Time frame: baseline and 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • EMS

    Hortolândia, São Paulo, Brazil

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.